On Dec. 10, 2020, Moderna announced that the first adolescent participants had been dosed in the Phase 2/3 study of mRNA-1273, the Companyﾒs vaccine candidate against COVID-19, in adolescents ages 12 to less than 18.

The study was conducted in collaboration with the Biomedical Advanced Research and Development Authority.